<p>The mechanism that attempts to distribute growth factors in tissue engineering and cancer therapies is controlled release systems (CRS). Angiogenesis, differentiation, and even proliferation are cellular events that are completely dependent on growth factors. Yet, their therapeutic value is challenging to maintain due to short half-life and rapid disintegration. By regularly and locally providing growth factors, CRS can match the body’s physiological patterns of release. When CRS is under control, it uses tissue regeneration for angiogenesis and gives the body some of the most important growth factors, like vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMPs), and transforming growth factor beta (TGF-β), which help with bone growth and tissue repair. Hydrogels, microspheres, and nanoparticles, widely used as a CRS platform, possess biocompatibility and modifiable release kinetics. Particularly focused on inhibiting tumour angiogenesis and enhancing chemotherapy efficiency, CRS provides a treatment that activates growth factors. Among the many stimuli-responsive systems that allow for the spatiotemporal dynamics of the differentiation factors in the milieu of the tumour is pH-sensitive enzyme-responsive CRS. In addition, the design of such CRS appears to allow for such development factor therapy to be patient specific. However, to effectively integrate CRS into clinical practice, we must address concerns about growth factor instability, scalability, and other regulatory issues. Taking everything into account, CRS serves as an excellent tool for enhancing growth factor-driven cancer therapy and tissue regeneration, ultimately offering new horizons for personalized medicine and better patient care.</p>